London Research & Pharmaceuticals Archives | Be Korea-savvy
London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

London Research & Pharmaceuticals (LRP) Presents the Advancement of LRP-661, Their Lead Drug Candidate, at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) Conference in Madrid, Spain, 5-8 May 2024

LONDON, Ontario, Jun. 10 (Korea Bizwire) — London Research & Pharmaceuticals presented notable pre-clinical data about its lead compound, LRP-661, also known as Cannabidiol Sulphate (CBDS), at the Seventeenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII) conference in Madrid, Spain, May 5th to May 8th, 2024. LRP-661’s data highlights its superior safety, [...]

London Research & Pharmaceuticals Presents the Advancement of LRP-661, Their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

London Research & Pharmaceuticals Presents the Advancement of LRP-661, Their Oral Cannabidiol Sulphate Drug Candidate at the Prestigious Epilepsy Therapies & Diagnostics Development (ETDD) XVII Conference in Miami

LONDON, Ontario, April 15, 2024 (Korea Bizwire) – London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters. CBDS maintains improved oral formulation capabilities vs cannabidiol, including tablet and water-based solutions. When compared against the currently available oral solution [...]